Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Kidney Int. 2009 Feb 18;75(9):936–944. doi: 10.1038/ki.2009.9

Figure 1. Effect of treatment on kidney injury.

Figure 1

Effect of treatment on (a) kidney weight, (b) glomerular sclerosis, (c) tubulointerstitial fibrosis, and (d) renal vascular modeling. For post hoc comparisons, *P < 0.01 versus sham, †P < 0.05 versus uninephrectomy (Neph), ‡P < 0.05 versus uninephrectomy + spironolactone (SPL), §P < 0.05 versus uninephrectomy + FAD286, ||P < 0.05 versus uninephrectomy + Ang II + spironolactone, P < 0.05 versus uninephrectomy + Ang II + FAD286. Masson’s trichrome (original magnification ×100) of the kidney in (e) control, (f) Ang II/salt-treated, (g) Ang II/salt + spironolactone-treated, and (h) Ang II/salt + FAD286-treated. The asterisks in (f) denote areas of tubulointerstitial fibrosis.